Clinical audit of breast cancer care at the Benavides Cancer Institute, University of Santo Tomas Manila, Philippines: Part 1, methods and tools

This article was published in the following Dove Press journal:
Clinical Audit
5 January 2015
Number of times this article has been viewed

Background: The prevalence and incidence of breast cancer has been increasing worldwide. It has been reported that the Philippines has the highest number of cases in Asia, and breast cancer is now the leading cause of death in the country. This study protocol presents the methodological plan for a quality improvement study that will assess the current practice of breast cancer examination, diagnosis, and management at one of the leading cancer institutions in the Philippines, the University of Santo Tomas Hospital-Benavides Cancer Institute (USTH-BCI), and map with standards of care, in order to identify areas that would need improvement to facilitate best practice care for breast cancer patients.

Methods: This study has been approved by the Institutional Review Board of the University of Santo Tomas Hospital. A breast cancer working group has been established (Benavides Cancer Institute Breast Cancer Working Group [BCIBC-WG]) during a 1 day meeting of cancer specialists at USTH-BCI. The meeting was facilitated by both international and local methodologists in the field of evidence-based practice and quality improvement. A quality improvement plan and a clinical audit protocol for assessing current practice were drafted during this meeting. The clinical audit of current breast cancer care will be undertaken at USTH-BCI using medical records review. Clinical indicators of outcomes were identified and typical patient journeys were mapped to develop the data collection/extraction form. The data collection forms were sent to experts for face and content validation, to ensure a valid and comprehensive collection of the data. The form was revised as needed. Three hundred and eighteen (318) breast cancer cases were seen at USTH-BCI in the year 2012, and all 318 records will be reviewed as decided by the group. A reliability procedure will be undertaken among data collectors of the study and pilot testing procedure will be undertaken to test the feasibility of the data collection methods. Data will be analyzed and reported using means and percentages as appropriate. Missing data will also be reported in order to identify strategies to ensure completeness of medical records in the future.

Keywords: breast cancer, audit, quality improvement, developing countries, protocol

Background: The increasing prevalence and incidence of cancer worldwide is alarming. In the United States alone, the prevalence of cancer in 2011 was 12,549,000.1 In less developed countries, the incidence of cancer is projected to increase from 56% of world cases in 2008 to greater than 60% by 2030. Cancer is also the leading cause of death globally. The World Health Organization reports that the number of deaths due to cancer is projected to increase by 45% from 2007 to 2030 (from 7.9 million to 11.5 million deaths).2 With the alarming increase in the prevalence and incidence of cancer and the rate of mortality due to cancer worldwide, much research has been done on identification

Correspondence: Janine Margarita Dizon
University of Santo Tomas Hospital, Manila, Philippines
Tel +63 2 406 1611 extn 4035 or 8454
Fax +63 2 740 9713
Email jmrdizon@yahoo.com

Jayson Co
University of Santo Tomas Hospital, Manila, Philippines
Tel +63 922 575 5558
Email j_c_polar@yahoo.com

Clinical Audit 2015:7 1–12
© 2015 Sy-Ortin et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
of risk factors in medical science research, one third of cases can be prevented, one third can be diagnosed early and thus managed early, and one third can be treated. However, this is only possible if management and treatment provided are consistent with evidence-based standards of care.

In the Philippines, cancer was one of the leading causes of morbidity and mortality in 2002: the leading cancer types are lung, breast, cervix, liver and colon. More recently, the Philippines’ Department of Health and the Philippine Cancer Society have reported that breast cancer is now the leading cancer type in the country and accounts for the highest incidence rate in Asia. Thus, the Philippines’ Department of Health, in partnership with the Philippine Cancer Society has developed programs in relation to screening, prevention, and management of cancer. Programs such as free screening, medicines for poor women diagnosed early with breast cancer, and the “Z Benefit Package of PhilHealth” were developed and implemented to address the alarming increase in breast cancer morbidity and mortality.

The University of Santo Tomas Hospital (USTH), one of the leading private health institutions in the Philippines, established the Benavides Cancer Institute (BCI) in 2006. The mission of the USTH-BCI is to strengthen the national cancer care program and provide comprehensive and multidisciplinary cancer care for diagnosis, treatment and prevention. Consistent with its mission, the USTH-BCI is continuously planning and strategizing ways to identify and deliver the best cancer care in the Philippines.

As medical science research has reported that cancer can be prevented, diagnosed early, and treated if care management and treatment programs are consistent with evidence-based guidelines, the USTH-BCI developed a research project that will assess current practice and then map current practice with existing evidence-based guidelines for breast cancer care such as the National Comprehensive Cancer Network (NCCN) Guidelines for breast cancer. USTH-BCI agreed to use the NCCN guidelines as standard of care to underpin health care provided to patients. However, it is not known whether the standards of care are being adhered to or complied with by all health professionals involved in the care of breast cancer patients. There is much discussion in the literature regarding the availability of evidence-based standards of care and the existing gap in compliance with the standards. For instance, whilst guideline adherence was associated with improved survival, one study reports that guideline adherence was low for patients with triple negative breast cancer. Another one reports less than half of women with breast cancer completed the recommended therapy. Thus, it is very important to assess whether existing practice follows the recommended standards, and then later, plan for strategies that would address the gaps and plan for sustainable efforts in the long term to improve clinical outcomes of care.

This may be an ambitious project but it could be a milestone in clinical practice and health care as this is the first attempt to evaluate current practices in breast cancer care in the Philippines. This is valuable because identifying current practices allows: 1) identification of relevant data items to be used as basis for assessing breast cancer care delivery; 2) identification of gaps which are useful in identifying areas which need improvement; 3) opportunities for better patient outcomes and better utilization of resources, especially in developing countries, such as the Philippines, with limited resources and lastly; 4) change and improve health policies in order to standardize health services and improve the health system, thus, championing best breast cancer care in the Philippines.

Objectives
This study protocol presents the methods for undertaking a quality improvement project that will describe the current practice of breast cancer examination, diagnosis, and management at the USTH-BCI, and map whether current practice is consistent with evidence based standard of care.

Methods
Ethics
Ethical approval was obtained from the Institutional Review Board of the USTH, Manila, Philippines.

Study design and setting
A clinical audit study using medical record review will be undertaken to address the study objectives. The clinical audit will be undertaken at the USTH-BCI.

Reference population
Patients with breast cancer seen at USTH-BCI can come from any of the following:
1. Patients in the clinical division of the USTH and referred to BCI for screening/evaluation, diagnosis/staging and treatment and management
2. Patients seen by a medical doctor within USTH and referred to BCI for diagnosis/staging and then for treatment and management
3. Patients diagnosed elsewhere in the Philippines and referred for breast cancer treatment and management from other institutions in the Philippines.
Patient with mammogram findings suspecting malignancy OR any of the following symptoms:

1. Breast mass
2. Breast asymmetry
3. Nipple discharge
4. Nipple bleeding
5. Nipple retraction
6. Skin dimpling
7. Breast pain
8. Axillary mass

Figure 1 (Continued)
Figure 1 Typical patient journey of patients with breast cancer.

Note: Patients may be referred to USTH-BCI at any point in the patient journey.

Abbreviations: USTH-BCI, University of Santo Tomas Hospital-Benavides Cancer Institute; LCIS, lobular carcinoma in situ; MRI, magnetic resonance imaging; Her2neu, human epidermal growth factor receptor 2; CT, computed tomography; Mets, metastasis; BCT, breast conservation therapy; CNB, core needle biopsy; ER, estrogen receptor; PR, progesterone receptor; FNAB, fine needle aspiration biopsy; DCIS, ductal carcinoma in situ.

Sampling method and sample size
A total of 318 patients with breast cancer were seen at BCI for the year 2012. As 318 is a manageable number of breast cancer patient cases, the group decided to consider all these cases for inclusion in the audit, thus using census sampling. This will allow 100% statistical power and accuracy in describing the current practice in different categories of breast cancer care provided by BCI.15

Working group
The clinical audit proposal was formulated by the BCI Breast Cancer Working Group (BCIBC-WG) consisting of
key health care personnel involved in breast cancer care at USTH-BCI (Teresa SyOrtin, MD, chair of BCI; Priscilla B Caguioa, MD; Clevelinda Calma, MD; Eugene Regala, MD; Kathleen Baldivia, MD; Rowen Yolo, MD; Michael A Mejia, MD; Karl Morales, MD; Josefino Sanchez, MD; Ray Malilay, MD; Ida Marie Tabangay-Lim, MD; Jocelyn Que, MD; Joycelyn Bautista, MD; Warren Bacorro, MD; and Jayson L Co, MD; and methodologists in the area of quality improvement and evidence based practice, (JRD, the project leader; KG, an external collaborator; and CGS, a local evidence based practice [EBP] champion). The BCIBC-WG held a 1 day meeting on quality improvements and audits, role of clinical guidelines in improving quality of health care services, and planning the quality improvement proposal of BCI.

### Identification of patient journeys

In order to identify the current practices in breast cancer care at BCI a typical patient journey was identified by the BCIBC-WG. Patient journeys are visualizations of the usual flow of relevant processes a patient undergoes when seen in the facility. A copy of the patient journey was then sent to other health care personnel involved in breast cancer care for validation of the processes. Thus, the patient journey presented in Figure 1 has been validated by all involved in breast cancer care at BCI and will be the basis of this clinical audit.

### Audit data items

The BCIBC-WG has identified an agreed list of items to be included in the clinical audit to obtain a comprehensive profile of breast cancer care at BCI (Tables 1–3).

### Data collection methods

#### Data collection tool

A standard data collection form (Supplementary materials) will be used to retrieve the relevant audit items from the clinical audit.

### Table 1 Profile of breast cancer patients seen at USTH-BCI

<table>
<thead>
<tr>
<th>A. Patient profile</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Age</td>
</tr>
<tr>
<td>2. Sex</td>
</tr>
<tr>
<td>3. Specific diagnosis (laterality, histologic subtype, stage, T-stage, N-stage, M-stage)</td>
</tr>
<tr>
<td>4. Ethnicity</td>
</tr>
<tr>
<td>5. Geographical location (region)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B. History and physical examination</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Who conducted the history and physical examination?</td>
</tr>
<tr>
<td>a. GP</td>
</tr>
<tr>
<td>b. Surgeon</td>
</tr>
<tr>
<td>c. GYN</td>
</tr>
<tr>
<td>d. Others</td>
</tr>
<tr>
<td>2. Length of referral from the attending physician to the surgeon</td>
</tr>
<tr>
<td>a. &lt;1 week</td>
</tr>
<tr>
<td>b. &gt;1 week</td>
</tr>
<tr>
<td>c. &gt;1 month</td>
</tr>
<tr>
<td>d. Others</td>
</tr>
<tr>
<td>3. And from which institution was the patient coming from</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. Elements in the history taking</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Family history of CA</td>
</tr>
<tr>
<td>b. OB history</td>
</tr>
<tr>
<td>1. menstrual history</td>
</tr>
<tr>
<td>2. hormonal therapy</td>
</tr>
<tr>
<td>3. parity</td>
</tr>
<tr>
<td>4. others</td>
</tr>
<tr>
<td>c. Previous history of mammograms (number and results)</td>
</tr>
<tr>
<td>d. Previous surgeries</td>
</tr>
<tr>
<td>e. Other malignancies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. Physical examination</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Description of breast mass</td>
</tr>
<tr>
<td>1. size</td>
</tr>
<tr>
<td>2. laterality</td>
</tr>
<tr>
<td>3. quadrant</td>
</tr>
<tr>
<td>4. clock position</td>
</tr>
<tr>
<td>5. distance from the nipple (cm)</td>
</tr>
<tr>
<td>6. skin changes</td>
</tr>
<tr>
<td>7. mobility</td>
</tr>
<tr>
<td>b. Axillary nodes (if palpable, number and mobility)</td>
</tr>
<tr>
<td>c. Supracavicular area</td>
</tr>
<tr>
<td>d. Chest PE (auscultatory findings)</td>
</tr>
<tr>
<td>e. Abdominal PE (liver, spleen)</td>
</tr>
</tbody>
</table>

### Table 2 Clinical audit of current practice on diagnosing/staging of patients with breast cancer at USTH-BCI

<table>
<thead>
<tr>
<th>A. Biopsy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Method of biopsy used</td>
</tr>
<tr>
<td>a. Fine needle aspiration biopsy (FNAB)</td>
</tr>
<tr>
<td>b. Core needle biopsy with ER/PR/Her2neu</td>
</tr>
<tr>
<td>c. Others</td>
</tr>
<tr>
<td>2. Number of biopsies conducted to arrive at a diagnosis</td>
</tr>
<tr>
<td>3. Length of time from collection of specimen to specimen being received by the pathologist to arriving at a diagnosis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B. Staging and prognostic and predictive characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Clinical staging</td>
</tr>
<tr>
<td>a. Mammography</td>
</tr>
<tr>
<td>b. Physical examination</td>
</tr>
<tr>
<td>c. Ultrasound</td>
</tr>
<tr>
<td>2. Pathologic staging</td>
</tr>
<tr>
<td>a. Histologic type</td>
</tr>
<tr>
<td>b. Grading</td>
</tr>
<tr>
<td>3. Biologic staging</td>
</tr>
<tr>
<td>a. ER</td>
</tr>
<tr>
<td>b. PR</td>
</tr>
<tr>
<td>c. Her2neu, IHC</td>
</tr>
<tr>
<td>d. Her2neu FISH</td>
</tr>
</tbody>
</table>

**Abbreviations:** USTH-BCI, University of Santo Tomas Hospital-Benavides Cancer Institute; GP, General Practitioner; GYN, gynecologist; CA, cancer; OB, obstetrics and gynecology; PE, physical examination; ER, estrogen receptor; PR, progesterone receptor; Her2neu, human epidermal growth factor receptor 2; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization.
Table 3 Clinical audit of treatment and management of patients with breast cancer referred to USTH-BCI

A. Date since first diagnostic exam to start of treatment
B. Multidisciplinary consultation
   1. Breast tumor boards
   2. Multidisciplinary patient/family meeting
   3. Specialty disciplines attending the multidisciplinary consultation
C. Stages of breast cancer: 0, 1, 2, 3, 4
D. Stage 0
   1. LCIS or DCIS
   2. If LCIS, procedures
      a. Genetic counselling
      b. Surveillance
      c. Chemo prevention
      d. Prophylactic surgery
3. If DCIS,
   a. Surgical procedure
      1. Lumpectomy
      2. Axillary lymph nodes dissection
      3. Simple mastectomy
      4. Modified radical mastectomy
   b. Adjuvant therapy given
   c. Tamoxifen given
E. Stage 1 and 2 by PE
   1. Symptom metastatic work ups done
F. Stage 3 by PE
   1. Mandatory tests done
      a. Chest X-ray
      b. Liver ultrasound
      c. Bone scan
2. Optional tests done
   a. Chest and upper abdominal CT
3. Appropriate surgical management given
   a. Fulfills BCT criteria
   b. Preference and reason for preference
4. Surgical procedure done (BCS or MRM)
5. If BCS,
   a. Pre-BCS treatment
      1. Chemotherapy
      2. Hormonotherapy
      3. Trastuzumab
   b. Adjuvant systemic therapy
      1. Chemotherapy
      2. Hormonotherapy
      3. Trastuzumab
   c. Adjuvant radiotherapy
6. If MRM,
   a. Indications noted (>0.5 cm, pN+, ER/PR (-), Her2neu+, triple negative)
   b. Adjuvant systemic therapy
      1. Chemotherapy
      2. Hormonotherapy
      3. Trastuzumab
   d. Adjuvant radiotherapy
G. Clinical stage III B-IIIC
   1. Neoadjuvant systemic therapy
      1. Chemotherapy
      2. Hormonotherapy
      3. Trastuzumab

(Continued)

Table 3 (Continued)

2. Surgery
   a. Adjuvant systemic therapy
      1. Chemotherapy
      2. Hormonotherapy
      3. Trastuzumab
   b. Adjuvant radiotherapy
   3. If metastatic, referral to palliative care
   4. Other treatment options
   5. If with brain metastasis, referral to neurosurgeon
H. Stage 4
   1. Referral to palliative care
   2. Referral for other options
I. Phyllodes
   1. Managed accordingly
J. Surveillance
   1. Date since surgery
   2. Date since last chemotherapy/adjuvant therapy
   3. Follow-up date:
      No evidence of disease
      Local recurrence
      Local recurrence/distinct metastases
      Distant metastases

Abbreviations: USTH-BCI, University of Santo Tomas Hospital-Benavides Cancer Institute; LCIS, lobular carcinoma in situ; DCIS, ductal carcinoma in situ; PE, physical examination; CT, computed tomography; BCT, breast conservation therapy; BCS, breast conservation surgery; MRM, modified radical mastectomy; ER, estrogen receptor; PR, progesterone receptor; Her2neu, human epidermal growth factor receptor 2.

patients’ medical records. This form includes information from patient demographics, history and physical examination, diagnosis/stages of breast cancer and management for breast cancer patients. Consent from the attending physicians will be obtained.

Validity of the data collection tool
The data collection form was sent to experts (surgeon, a medical oncologist and a pathologist) and comments were discussed in a meeting for face and content validation. This was to ensure that the data audit items to be retrieved from the medical records will answer the clinical audit objectives. Revisions were undertaken based on the validation procedure and sent back to the experts for approval.

Pilot testing the audit data collection process
The clinical audit data collection process will be pilot tested to ensure validity and reliability of the procedures. More specifically, the purposes of the pilot testing are as follows:
1. Test feasibility of the data collection methods
2. Estimate the amount of time and resources required to collect data
3. Check data for completeness.
<table>
<thead>
<tr>
<th>Quality indicators</th>
<th>Data elements</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diagnosis</strong></td>
<td></td>
</tr>
<tr>
<td>Completeness of prognostic/predictive characterization</td>
<td>Proportion of patients (invasive cancer cases) for which the following prognostic/predictive parameters have been recorded: 1. Histologic type 2. Grading 3. Her2 testing</td>
</tr>
<tr>
<td></td>
<td>Proportion of patients (invasive cancer cases) with primary surgery for which the following prognostic/predictive parameters have been recorded: 1. Histologic type 2. Grading 3. ER 4. Her2 testing 5. Pathologic testing (T and N) 6. Size in mm for invasive component 7. Peritumoral vascular invasion 8. Distance to nearest radial margin</td>
</tr>
<tr>
<td></td>
<td>Proportion of patients (non-invasive cancer cases) for which the following prognostic/predictive parameters have been recorded: 1. Dominant histologic pattern 2. Size in mm (best pathology or radiology estimate if 2 stage pathology) 3. Grading 4. Distance to nearest radial margin</td>
</tr>
<tr>
<td><strong>Waiting time</strong></td>
<td>Date from first diagnostic examination to date of surgery or first treatment</td>
</tr>
<tr>
<td><strong>Surgery and loco-regional treatment</strong></td>
<td></td>
</tr>
<tr>
<td>Multidisciplinary discussion</td>
<td>Proportion of cancer patients to be discussed by a multidisciplinary team</td>
</tr>
<tr>
<td>Appropriate surgical approach</td>
<td>Proportion of patients (invasive cancer cases) who received a single (breast) operation for the primary tumor</td>
</tr>
<tr>
<td>Postoperative RT</td>
<td>Proportion of patients (invasive cancer cases) who received postoperative RT after surgical resection of primary tumor and appropriate staging/surgery PROPORTION OF PATIENTS WITH INVOLVEMENT OF AXILLARY LYMPH NODES (pN2a) WHO RECEIVED POST-MASTECTOMY RADIOTHERAPY</td>
</tr>
<tr>
<td><strong>Avoidance of over treatment</strong></td>
<td></td>
</tr>
<tr>
<td>Overtreatment</td>
<td>Proportion of patients with invasive breast cancer not &gt;3 cm who underwent BCT</td>
</tr>
<tr>
<td><strong>Systemic treatment</strong></td>
<td></td>
</tr>
<tr>
<td>Appropriate hormonotherapy</td>
<td>Proportion of patients with endocrine sensitive invasive carcinoma who received hormonotherapy, out of those with diagnosis</td>
</tr>
<tr>
<td>Appropriate chemotherapy and other medical therapy</td>
<td>Proportion of patients with ER- and PR-carcinoma who received did not receive adjuvant hormonotherapy, out of those with diagnosis</td>
</tr>
<tr>
<td>Appropriate chemotherapy and other medical therapy</td>
<td>Proportion of patients with ER- (T&gt;1 cm or Node+) invasive carcinoma who received adjuvant chemotherapy, out of those with diagnosis</td>
</tr>
<tr>
<td>Appropriate chemotherapy and other medical therapy</td>
<td>Proportion of patients with N+ or N- T&gt;1 cm Her2neu+ (IHC3+ or +FISH) invasive carcinoma treated with chemotherapy and had adjuvant trastuzumab out of those with same diagnosis</td>
</tr>
<tr>
<td><strong>Staging, counseling, follow-up and rehabilitation</strong></td>
<td></td>
</tr>
<tr>
<td>Appropriate staging procedure</td>
<td>Proportion of women with stage 1 breast cancer who do not undergo metastatic staging tests</td>
</tr>
<tr>
<td>Appropriate staging procedure</td>
<td>Proportion of women with stage 3 breast cancer who undergo metastatic staging tests</td>
</tr>
<tr>
<td>Appropriate follow-up</td>
<td>Proportion of asymptomatic patients who undergo routine annual mammographic screening and clinical evaluation every 6 months in the first 5 years after the operation</td>
</tr>
<tr>
<td>Appropriate follow-up</td>
<td>Proportion of patients undergoing periodic history taking, physical examination and annual mammography</td>
</tr>
</tbody>
</table>

**Abbreviations:** Her2, human epidermal growth factor receptor 2; ER, estrogen receptor; RT, radiotherapy; BCT, breast conservation therapy; PR, progesterone receptor; IHC3, immunohistochemistry 3; FISH, fluorescence in situ hybridization.
Data collectors

Two to three data collectors will be identified to retrieve the audit items from the medical records. They should have experience in data recording or management to ensure ability to reliably extract the information needed. An orientation to the clinical audit project and training for data collection will be conducted with the data collectors. A reliability procedure will also be undertaken by asking the data collectors to complete data extraction of five sample cases independently. The inter-rater reliability for percentage of agreement recommended by Dixon and Pearce will be used to compute the reliability of the data collectors.15 This is done by dividing the number of bits of data for which there was complete agreement among the data collectors and the total number of bits of data (for example, 25 bits of data per case × 5 cases). Further training will be provided as needed based on the results of the reliability procedure.

Data handling

A purpose built MSExcel file will be constructed, which restricts the type of data which can be entered into each column. This will reduce data entry errors and ensure efficiency of data amalgamation. All patient cases to be included in the clinical audit will be provided with a code. This code will be used and entered as the patient case in the MSExcel file including all audit items retrieved from the patient medical records.

Auditing guidelines

Table 4 lists the quality indicators that will be used later to evaluate the outcome of current practice (relevant items extracted from the European Society of Breast Cancer Specialists Quality indicators in breast cancer position paper by Del Turco et al.).18

Data analysis

This will be undertaken by an independent statistician. Data will be reported using means and percentages as appropriate. Missing data will also be reported in order to identify strategies to ensure completeness of medical records in the future particularly when assessing adherence to guidelines.

Confidentiality

All data to be obtained from the medical records shall be kept confidential and will only be available to the working group.

Disclosure

The authors have no conflicts of interest to declare.

References

Supplementary material

Benavides Cancer Institute’s Breast Cancer Audit Form

PATIENT PROFILE

A. Profile

1. Name: ________________________________

2. Age: ________________________________

3. Gender: 
   [ ] Female [ ] Male

4. Final pathologic diagnosis: ________________________________

   • Laterality [ ] Right [ ] Left [ ] Bilateral
   • Histologic subtype [ ] IDC [ ] ILC [ ] Other ______
   • Stage [ ] 0 [ ] I [ ] II [ ] III [ ] IV
   • T-stage [ ] 1 [ ] 2 [ ] 3 [ ] 4
   • N-stage [ ] 0 [ ] 1 [ ] 2 [ ] 3
   • M-stage [ ] 0 [ ] 1

5. Ethnicity: ________________________________

6. Geographical Location (Region) by residence:
   [ ] NCR [ ] CAR [ ] ARM
   [ ] 1 [ ] 2 [ ] 3 [ ] 4-A [ ] 4-B [ ] 5 [ ] 6
   [ ] 7 [ ] 8 [ ] 9 [ ] 10 [ ] 11 [ ] 12 [ ] 13

B. History and physical examination

1. Who conducted the history taking?
   [ ] General Physician [ ] Surgeon [ ] Gynaecologist [ ] Others: ________________________________
   [ ] Specialist [ ] Trainee

2. Length of referral from the physician who took the history to the surgeon
   [ ] 1 week [ ] >1 week [ ] >1 month [ ] others:
   Reasons for delay: ________________________________
   From which institution: ________________________________

3. Elements of the history taking
   a. Family history of cancer
      1. [ ] With history OR [ ] Without history
      If with history, identify the site/s:
         a. ________________________________
         b. ________________________________
         c. ________________________________
   b. OB history
      1. [ ] With menstrual history OR [ ] Without menstrual history
      2. [ ] Hormone use OR [ ] No hormone use
         If+ hormone use, identify the type: ________________________________
      3. Parity
         [ ] 0 [ ] 1 [ ] 2 [ ] 3 [ ] 4 [ ] 5 [ ] 6 [ ] 7 [ ] 8 [ ] 9 [ ] 10 [ ] >10
      4. Others: ________________________________
   c. Previous history of mammogram
      1. [ ] With mammogram OR [ ] Without mammogram
If with mammogram, number of mammograms done:

[ ] 0 [ ] 1 [ ] 2 [ ] 3

2. Results of mammogram and identify classification checklist used:

_____________________________________

d. Previous history of surgery:

1. [ ] With history of surgery OR [ ] Without history of surgery
   If with history of surgery, identify:
   a. __________________________________________
   b. __________________________________________
   c. __________________________________________

e. Other malignancy

1. [ ] With other malignancy OR [ ] Without other malignancy
   If with other malignancy, identify:
   a. __________________________________________
   b. __________________________________________
   c. __________________________________________

e. Other malignancy

4. Elements of physical examination

a. Description of breast mass
   1. Size of breast mass: ________(cm)
   2. Laterality: [ ] Right [ ] Left
   3. Quadrant: [ ] Upper outer quadrant, [ ] Upper inner quadrant, [ ] Lower outer quadrant, [ ] Lower inner quadrant
   4. Clock position
      [ ] 3:00 o’clock [ ] 6:00 o’clock [ ] 9:00 o’clock [ ] 12:00 o’clock
   5. Distance from the nipple (cm): _____
   6. Skin changes:
      [ ] With skin changes OR [ ] Without skin changes
   7. Mass mobility:
      [ ] Fixed OR [ ] Mobile
   b. Presence of nodes:
      [ ] With axillary nodes OR [ ] With supraclavicular nodes
      If with nodes: number of nodes: ____ mobility: _____________
   c. Chest PE: _______________________________________________________________
   d. Abdominal PE: _______________________________________________________________

DIAGNOSIS AND STAGING

A. Biopsy

1. Method of biopsy used
   [ ] FNAB [ ] Core needle biopsy with ERA/PRA/Her2neu [ ] others
2. Number of biopsies to arrive at a diagnosis: _________________________
3. Date of collection of specimen: ___________________________________
4. Date of specimen received at pathology laboratory: ___________________________________
5. Date of diagnosis: ___________________________________

B. Staging and prognostic and predictive characteristics

1. Clinical staging
   [ ] Mammography [ ] Physical examination [ ] Ultrasound
2. Pathologic staging
   [ ] Histologic type [ ] Grading
3. Biologic staging
   [ ] ERA [ ] PRA [ ] Her2neu, iHC [ ] Her2neu FISH
MANAGEMENT OF BREAST CANCER

A. Multidisciplinary consultation:
   1. Multidisciplinary consultation done [ ] Yes OR [ ] No
   2. Type: [ ] breast tumor boards [ ] multidisciplinary patient/family meeting
   3. Attended by: ____________________________

B. Stage of breast cancer:
   1. Stage 0: [ ] LCIS OR [ ] DCIS
      a. If LCIS, what was done:
         [ ] genetic counselling [ ] surveillance [ ] chemo prevention [ ] prophylactic surgery
      b. If DCIS, what surgical procedure was done; check any that applies:
         [ ] lumpectomy [ ] axillary lymph node dissection [ ] simple mastectomy [ ] MRM
      c. Was adjuvant radiotherapy given, [ ] Yes [ ] No
      d. Was tamoxifen given, [ ] Yes [ ] No
   2. Stage 1 and 2 by PE
      a. Symptom directed metastatic work ups:
         [ ] chest x-ray
         [ ] liver ultrasound
         [ ] bone scan
         [ ] chest CT
         [ ] upper abdominal CT
         [ ] others, specify: _____________________________________________
         If metastatic proceed to __________
         If non-metastatic, proceed to Clinical stage I-IIIA (M0 on work up)
   3. Stage 3 by PE
      a. Mandatory:
         [ ] Chest x-ray
         [ ] Liver ultrasound
         [ ] Bone Scan
      b. Optional:
         [ ] Chest and upper abdominal CT
         If metastatic proceed to __________
         If non-metastatic IIIA, proceed to Clinical stage I-IIIA (M0 on work up)
         If non-metastatic IIIB-IIIC, proceed to Clinical stage IIIB-IIIC (M0 on work up)
      c. Appropriateness of surgical management:
         1. Fulfils BCT criteria: [ ] Yes [ ] No, [ ] Yes, except size
         2. Preference: [ ] BCT [ ] MRM, reason: ________________________________________
            ________________________________________
      d. Surgical procedure: [ ] BCS [ ] MRM
         If BCS,
         1. Was pre-BCS systemic treatment given: [ ] Yes [ ] No
            If Yes, check any that applies:
            [ ] chemotherapy
            [ ] hormonotherapy
            [ ] trastuzumab
         2. Was adjuvant systemic therapy given: [ ] Yes [ ] No
            If YES, check any that applies:
            [ ] chemotherapy
            [ ] hormonotherapy
            [ ] trastuzumab
3. Was adjuvant radiotherapy given: [ ] Yes [ ] No
   If MRM,
   1. Indications for adjuvant systemic therapy, check all that apply:
      [ ] >0.5 cm
      [ ] pN+
      [ ] ERA/PRA(-)
      [ ] Her2neu +,
      [ ] triple-negative
   2. Adjuvant systemic therapy given: [ ] Yes [ ] No
      If YES, check any that applies:
      [ ] chemotherapy
      [ ] hormonotherapy
      [ ] trastuzumab
   3. Was adjuvant radiotherapy given: [ ] Yes [ ] No

4. Clinical stage IIIB-IIIC
   a. Was neoadjuvant systemic therapy given [ ] Yes [ ] No
      If YES, check any that applies:
      [ ] chemotherapy
      [ ] hormonotherapy
      [ ] trastuzumab
   b. Was surgery done [ ] Yes [ ] No
      If surgery was done, was adjuvant systemic therapy given: [ ] Yes [ ] No
      If YES, check any that applies:
      [ ] chemotherapy
      [ ] hormonotherapy
      [ ] trastuzumab
   c. Was adjuvant radiotherapy given: [ ] Yes [ ] No

5. If metastatic, was palliative care referral done [ ] Yes [ ] No
   a. Were other treatment options aside from palliative care given [ ] Yes [ ] No
      Palliative systemic treatment
      [ ] chemotherapy
      [ ] hormonotherapy
      [ ] trastuzumab
      [ ] bone directed
      [ ] radiotherapy
      [ ] palliative surgery
      [ ] toilette mastectomy
   b. If with brain metastasis, was referral to neuro surgeon given [ ] Yes [ ] No